Background. Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric
LV hypertrophy (LVH) and impairment in diastolic function. We assess the relationship between
LVH and invasive indexes of diastolic function.
Methods. 21 HCM patients underwent cardiac catheterization to assess pulmonary capillary wedge pressure, LV end-diastolic pressure (measured by microtip catheters), and LV volumes (calculated by simultaneous radionuclide angiography). We calculated from LV pressure the time constant of isovolumetric relaxation (τ, variable asymptote method, ms), and from LV pressure and volume the constant of chamber stiffness (k, ml-1). LVH was assessed by different indexes: maximal wall thickness, number of hypertrophied LV segments, LVH index, and Wigle’s score.
Results. Wigle’s score was directly related to pulmonary capillary Wedge pressure (r=0.436, p=0.048), peak V wave of pulmonary capillary wedge pressure (r=0.503, p=0.024), LV end-diastolic pressure (r=0.643, p=0.002) and k (r=0.564, p=0.015). HCM patients were divided into 2 groups according to Wigle’s score: 10 with mild or moderate LVH (< 8), and 11 with severe LVH (≥ 8). HCM patients with severe LVH showed a higher pulmonary capillary Wedge pressure (15.1±7.2 vs 9.5±2.4, p=0.033), peak V wave of pulmonary capillary wedge pressure (20.7±4.6 vs 14.6±4.9, p=0.011), LV end-diastolic pressure (23.9±10.9 vs 10.6±2.5, p=0.002), k (0.0465±0.032 vs 0.015±0.007, p=0.022) and LV outflow tract gradient (72±36 mmHg vs 29±30 mmHg, p=0.01). τ was similar in the two groups. Other indexes of LVH were not related to diastolic function.
Conclusions. Wigle’s score is the only index of LVH that relates to invasive indices of diastolic function. (Heart International 2006; 2: 106-14)
Cardiomyopathy, Diastole, Hypertrophy
Sandro Betocchi, MD, FACC, FESC, Department of Clinical Medicine, Cardiovascular & Immunological Sciences, “Federico II” University School of Medicine, Via S. Pansini, 5, 80131 Naples – Italy, firstname.lastname@example.org
Share this Article
Related Content In Heart Failure
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Sodium–glucose Cotransporter 2 Inhibitors’ Rise to the Backbone of Heart Failure Management: A Clinical Review
Heart International. 2021;15(1):42-48 DOI: https://doi.org/10.17925/HI.2021.15.1.42
Heart failure (HF) is an increasingly prevalent clinical syndrome resulting from a variety of disease processes impeding the heart’s ability to effectively circulate blood. With advances in care and a steadily growing and aging population, HF management is becoming a foremost priority in developed nations like the USA, where HF is expected to affect more […]
Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions
Heart International. 2021;15(1):49-53 DOI: https://doi.org/10.17925/HI.2021.15.1.49
Heart failure (HF) is a highly prevalent and morbid disease in the USA, imposing a significant burden on patients, hospitals and the health system. The prevalence of HF continues to increase, with over 650,000 new HF cases diagnosed annually.1 There are over 6.2 million people with HF in the USA,2 with an expected increase to 8 million […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!